AFRM vs IREN

AFRM's Piotroski F-Score of 7/9 indicates strong operational health, but the absence of an Altman Z-Score raises concern about bankruptcy risk, particularly given a high Debt/Equity ratio of 2.59. The stock trades at a premium valuation (P/E 57.88 vs. sector average 30.46) despite mixed earnings quality, with recent Q/Q EPS growth at +213% but year-over-year EPS down 5.3%. Insider selling totaling $56.66M in the last six months signals bearish sentiment from management. While revenue and earnings growth remain robust (29.6% and 59.3% YoY), the lack of cash flow data and high leverage undermine financial stability. The current price of $46.88 is significantly above both the Graham Number ($13.95) and intrinsic value estimate ($23.9), suggesting a substantial valuation premium driven by growth expectations.

IREN Limited presents a deeply contradictory profile: explosive revenue growth of 355.4% YoY and a 3Y return of +1824.1% signal strong market momentum and potential disruption, yet fundamental red flags abound. The company reports a negative operating margin (-25.02%) and ROA of -0.01%, indicating severe profitability challenges despite a 75.99% profit margin—likely an accounting anomaly or non-operational gain. Valuation metrics are stretched, with a P/E of 26.65 and a Forward P/E of 136.38, far exceeding peers like BLK and SCHW, while insiders have sold $66.26M in shares recently, signaling concern at current levels. Analysts maintain a 'buy' recommendation with a $76.00 target, implying 64% upside, but the lack of earnings beats, negative operating leverage, and deteriorating price action (-31.8% over 1M) suggest significant risk in extrapolating recent performance.